Helen J. Ball

Helen J. Ball

Auto-generated profile, based on publicly available information

Helen J. Ball

Molecular Immunopathology Unit, Bosch Institute and School of Medical Sciences, University of Sydney, Sydney, New South Wales 2006, Australia

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2010 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
Yutang WangYutang Wang
Yutang Wang
HLHanzhong Liu
Hanzhong Liu
GMGavin McKenzie
Gavin McKenzie
Paul WittingPaul Witting
Paul Witting
JSJohannes-Peter Stasch
Johannes-Peter Stasch
RSRoland Stocker
Roland Stocker

1 July 2007 in Gene
Verified
Journal Article
Closed access
HBHelen J. Ball
Helen J. Ball
ASAngeles Sanchez-Perez
Angeles Sanchez-Perez
SWSilvia Weiser
Silvia Weiser
CAChristopher J.D. Austin
Christopher J.D. Austin
FAFlorian Astelbauer
Florian Astelbauer
NHNicholas H. Hunt
Nicholas H. Hunt

1 July 1992 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
HHH Herzog
H Herzog
YHY J Hort
Y J Hort
HBH J Ball
H J Ball
GHG Hayes
G Hayes
JSJ Shine
J Shine
LSL A Selbie
L A Selbie
Neuropeptide Y (NPY) is one of the most abundant neuropeptides in the mammalian nervous system and exhibits a diverse range of important physiological activities, including effects on psychomotor activity, food intake, regulation of central endocrine secretion, and potent vasoactive effects on the cardiovascular system. Two major subtypes of NPY receptor (Y1 and Y2) have been defined by pharmacological criteria. We report here the molecular cloning of a cDNA sequence encoding a human NPY receptor and the corrected sequence for a rat homologue. Analysis of this sequence confirms that the receptor is a member of the G protein-coupled receptor superfamily. When expressed in Chinese hamster ovary (CHO) or human embryonic kidney (293) cells, the receptor exhibits the characteristic ligand specificity of a Y1 type of NPY receptor. In the 293 cell line, the receptor is coupled to a pertussis toxin-sensitive G protein that mediates the inhibition of cyclic AMP accumulation. In the CHO cell line, the receptor is coupled not to the inhibition of adenylate cyclase but rather to the elevation of intracellular calcium. These results demonstrate that second messenger coupling of the NPY-Y1 receptor is cell type specific, depending on the specific repertoire of G proteins and effector systems present in any cell type.

1 March 2009 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
HBHelen J. Ball
Helen J. Ball
HYHajime J. Yuasa
Hajime J. Yuasa
CAChristopher J.D. Austin
Christopher J.D. Austin
SWSilvia Weiser
Silvia Weiser
NHNicholas H. Hunt
Nicholas H. Hunt

1 May 2006 in International Journal for Parasitology
Verified
Journal Article
Closed access
NHNicholas H. Hunt
Nicholas H. Hunt
JGJacob Golenser
Jacob Golenser
TCTailoi Chan-Ling
Tailoi Chan-Ling
SPSapan Parekh
Sapan Parekh
RDRae Caroline D
Rae Caroline D
HBHelen J. Ball
Helen J. Ball

9 October 2014 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
HBHelen J. Ball
Helen J. Ball
FFFelicita F. Fedelis
Felicita F. Fedelis
SBSupun M. Bakmiwewa
Supun M. Bakmiwewa
NHNicholas H. Hunt
Nicholas H. Hunt
HYHajime J. Yuasa
Hajime J. Yuasa
Indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO) are tryptophan-degrading enzymes that have independently evolved to catalyze the first step in tryptophan catabolism via the kynurenine pathway. The depletion of tryptophan and formation of kynurenine pathway metabolites modulates the activity of the mammalian immune, reproductive and central nervous systems. IDO and TDO enzymes can have overlapping or distinct functions depending on their expression patterns. The expression of TDO and IDO enzymes in mammals differs not only by tissue/cellular localization but also by their induction by distinct stimuli. To add to the complexity, these genes also have undergone duplications in some organisms leading to multiple isoforms of IDO or TDO. For example, many vertebrates, including all mammals, have acquired two IDO genes via gene duplication, although the IDO1-like gene has been lost in some lower vertebrate lineages. Gene duplications can allow the homologs to diverge and acquire different properties to the original gene. There is evidence for IDO enzymes having differing enzymatic characteristics, signaling properties and biological functions. This review analyses the evolutionary convergence of IDO and TDO enzymes as tryptophan-catabolizing enzymes and the divergent evolution of IDO homologs to generate an enzyme family with diverse characteristics not possessed by TDO enzymes, with an emphasis on the immune system.